Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo allies on hybrid drugs

Executive Summary

Asubsidiary of Endo is allying with US-based ophthalmics and injectables specialist Nevakar to develop and market five “differentiated” sterile injectable products in the US and Canada. Nevakar will take charge of developing and filing the products, using in the US the 505(b)(2) hybrid new drug application (NDA) pathway.

You may also be interested in...



Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance

Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.

Endo’s Par Delivers On Nevakar Alliance With First Launch

Endo’s Par has announced the first launch under a longstanding US collaboration with 505(b)(2) specialist Nevakar, in the form of pre-mixed ephedrine sulfate injection in a ready-to-use 50mg/10ml single-use vial.

Endo Starts Search For Campanelli’s Successor

With Endo’s CEO Paul Campanelli intending to step down for personal reasons, the US brands and generics player’s board has started to look for external and internal candidates to take over.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

GB001128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel